ABRS Intelligence continuously monitors rare disease research across scientific databases worldwide — identifying overlooked drug repurposing opportunities before they become obvious to the field.
The scientific literature for rare diseases spans millions of documents across databases that no single team can monitor continuously. Promising signals get buried. Years pass before the right connection is made — if it ever is.
ABRS Intelligence was built to close this gap. Our platform continuously scans the scientific record, applying multiple independent analytical frameworks to surface compounds with strong computational evidence for diseases they have never been tested in.
The result: actionable intelligence that reaches your R&D team before competitors are even looking.
Every signal is evaluated across multiple independent analytical dimensions before reaching you.
Our system processes new scientific publications, clinical trial data, genomic databases, and compound bioactivity records around the clock — capturing signals the moment they emerge in the literature.
Always activeEvery candidate is scored through multiple independent analytical frameworks simultaneously. A compound that converges across all dimensions carries a fundamentally different weight than one driven by a single data source.
Multi-dimensionalWe surface specifically the candidates that are already approved for other indications, carry established safety profiles, and have never been studied in the target disease. The shortest path from insight to IND.
Actionable signalsBefore trusting a signal, trust the system that generates it. ABRS Intelligence has been validated against established ground truths — compounds we know are correct. When the system independently surfaces FDA-approved therapies as top candidates without prior configuration, it confirms the methodology is working. The real value is what it finds next.
The only FDA-approved ALS therapy for over two decades. Ranked independently by ABRS as a top candidate — without configuration or prior knowledge of existing therapies.
Ground truth confirmedFirst FDA-approved SMA therapy. Ranked #1 by ABRS with the highest composite score in the portfolio — independently, from raw scientific data alone.
Ground truth confirmedFDA-approved for rheumatoid arthritis. Maximum network medicine proximity connecting IL-1 signaling to ALS neuroinflammation pathways. Zero clinical trials in ALS. An uncontested field.
Novel — uncontestedExpand your pipeline without expanding your research team. Receive continuous intelligence on repurposing candidates for diseases in your therapeutic focus — before competitors are looking.
Allocate research funding with confidence. Our intelligence identifies which compounds have the strongest scientific case for your disease — and which development paths carry the lowest risk.
Identify licensing and co-development opportunities ahead of the market. We surface compounds where evidence is converging but clinical work hasn't begun — maximum optionality, minimum competition.
We prepare a sample report for any disease in our monitoring portfolio.
No commitment. See the depth of analysis before deciding.